Suchergebnisse - Javier Pinilla‐Ibarz

Treffer weiter einschränken
  1. 1
    Signaling Networks Associated with BCR–ABL–Dependent Transformation

    Signaling Networks Associated with BCR–ABL–Dependent Transformation von Lori Hazlehurst, Nadine N. Bewry, Rajesh R. Nair, Javier Pinilla‐Ibarz

    Veröffentlicht 2009
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  2. 2
    Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

    Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies von Jessica M. McDaniel, Javier Pinilla‐Ibarz, Pearlie K. Epling‐Burnette

    Veröffentlicht 2012
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  3. 3
    Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia

    Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia von Wael Gamal, Melanie Mediavilla-Varela, Vishaal Kunta, Eva Sahakian, Javier Pinilla‐Ibarz

    Veröffentlicht 2025
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  4. 4
    Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

    Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance von Nadine N. Bewry, Rajesh R. Nair, Michael F. Emmons, David Boulware, Javier Pinilla‐Ibarz, Lori A. Hazlehurst

    Veröffentlicht 2008
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management

    Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management von Jorge E. Cortés, Carlos A. Jiménez, Michael J. Mauro, Alex Geyer, Javier Pinilla‐Ibarz, Benjamin D. Smith

    Veröffentlicht 2016
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  6. 6
    <scp>WT</scp>1 vaccination in <scp>AML</scp> and <scp>MDS</scp>: A pilot trial with synthetic analog peptides

    <scp>WT</scp>1 vaccination in <scp>AML</scp> and <scp>MDS</scp>: A pilot trial with synthetic analog peptides von Jason Brayer, Jeffrey E. Lancet, John J. Powers, Alan F. List, Lodovico Balducci, Rami S. Komrokji, Javier Pinilla‐Ibarz

    Veröffentlicht 2015
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia

    Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia von Onyee Chan, Chetasi Talati, Leidy Isenalumhe, Samantha Shams, Lisa Nodzon, Michael G. Fradley, Kendra Sweet, Javier Pinilla‐Ibarz

    Veröffentlicht 2020
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  8. 8
    A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

    A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia von Kathleen N. S. Cathcart, Javier Pinilla‐Ibarz, Tatyana Korontsvit, Joseph E. Schwartz, Victoriya Zakhaleva, Esperanza B. Papadopoulos, David A. Scheinberg

    Veröffentlicht 2003
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  9. 9
    Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells

    Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells von Rena J. May, Tao Dao, Javier Pinilla‐Ibarz, Tatyana Korontsvit, Victoriya Zakhaleva, Rong H. Zhang, P. Maslak, David A. Scheinberg

    Veröffentlicht 2007
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance

    Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance von Hagop M. Kantarjian, Phillipp le Coutre, Jorge E. Cortés, Javier Pinilla‐Ibarz, Arnon Nagler, Andreas Hochhaus, Shinya Kimura, Oliver G. Ottmann

    Veröffentlicht 2010
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  11. 11
    A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

    A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease von Kendra Sweet, Lori Hazlehurst, Eva Sahakian, John J. Powers, Lisa Nodzon, Fadi Kayali, Kelly A. Hyland, Ashley Nelson, Javier Pinilla‐Ibarz

    Veröffentlicht 2018
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  12. 12
    Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of Real-World Patients with CLL

    Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of... von Constantine S. Tam, Javier Pinilla Ibarz, Volkan Karakuş, Catherine Moura, Miguel Arturo Pavlovsky, Fernando Nicolás Piotrowsky, Martin Šimkovič, Andrew Smith, Stephan Stilgenbauer

    Veröffentlicht 2022
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  13. 13
    Inhibition of ER stress–associated IRE-1/XBP-1 pathway reduces leukemic cell survival

    Inhibition of ER stress–associated IRE-1/XBP-1 pathway reduces leukemic cell survival von Chih-Hang Anthony Tang, Sujeewa Ranatunga, Crystina L. Kriss, Christopher L. Cubitt, Jianguo Tao, Javier Pinilla‐Ibarz, Juan R. Del Valle, Chih‐Chi Andrew Hu

    Veröffentlicht 2014
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  14. 14
    NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia

    NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia von Susan O’Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla‐Ibarz, Jerald P. Radich, Paul J. Shami, Benjamin D. Smith, David S. Snyder, Hema Sundar, Moshe Talpaz, Meir Wetzler

    Veröffentlicht 2011
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

    The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance von Alejandro Villagra, Fengdong Cheng, Hongwei Wang, Ildelfonso Suarez, Michelle Glozak, Michelle Maurin, Danny Nguyen, Kenneth L. Wright, Peter Atadja, Kapil N. Bhalla, Javier Pinilla‐Ibarz, Edward Seto, Eduardo M. Sotomayor

    Veröffentlicht 2008
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  16. 16
    Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison

    Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison von Kristin M. Phillips, Javier Pinilla‐Ibarz, Eduardo M. Sotomayor, Morgan Lee, Heather Jim, Brent J. Small, Lubomir Sokol, Jeffrey E. Lancet, Sara Tinsley, Kendra Sweet, Rami S. Komrokji, Paul B. Jacobsen

    Veröffentlicht 2012
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  17. 17
    Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

    Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes von Asmita Mishra, Maria Corrales‐Yepez, Najla Al Ali, Mohamed A. Kharfan‐Dabaja, Eric Padron, Ling Zhang, Pearlie K. Epling‐Burnette, Javier Pinilla‐Ibarz, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji

    Veröffentlicht 2013
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    PB1945: PATIENT PERSPECTIVES ON CLL TREATMENT SIDE EFFECTS: A SUB-ANALYSIS OF THE VOICE SURVEY

    PB1945: PATIENT PERSPECTIVES ON CLL TREATMENT SIDE EFFECTS: A SUB-ANALYSIS OF THE VOICE SURVEY von Constantine S. Tam, Javier Pinilla‐Ibarz, Volkan Karakuş, Miguel Arturo Pavlovsky, Stephan Stilgebauer, Martin Šimkovič, Ana Cristina Fenili, Miguel Augusto Miroli, Carolina García-Castillo, Kathryn Huntley, Catherine Moura, Fernando Piotrowski, Mervat Mattar

    Veröffentlicht 2023
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL

    Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL von Constantine S. Tam, Javier Pinilla‐Ibarz, Carolina García-Castillo, Ana Cristina Fenili, Kathryn Huntley, Volkan Karakuş, Mervat Mattar, Miguel Augusto Miroli, Catherine Moura, Miguel Arturo Pavlovsky, Fernando Piotrowski, Martin Šimkovič, Stephan Stilgenbauer

    Veröffentlicht 2023
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

    Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib von Jorge E. Cortés, Andreas Hochhaus, Philipp D. le Coutre, Gianantonio Rosti, Javier Pinilla‐Ibarz, Elias Jabbour, Kathryn Gillis, Richard C. Woodman, Rick E. Blakesley, Francis J. Giles, Hagop M. Kantarjian, Michele Baccarani

    Veröffentlicht 2011
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: